ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced it has added $13 million in new capital to its Series D financing, bringing the total round to $98 million. The second close includes new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, as well as increased backing from existing investor Innovation Industries.
The additional financing builds on the $85 million ViCentra raised in September 2025 and follows what the company described as a year of significant commercial and operational progress. ViCentra said it will use the expanded funding to scale manufacturing, deepen commercial execution across Germany, the Netherlands, and France, and accelerate preparations for U.S. market access for a next-generation version of Kaleido.
ViCentra positions Kaleido as a differentiated option in the insulin delivery market, emphasizing a compact form factor and a consumer-technology aesthetic. The company says Kaleido is designed to feel like personal technology and features customizable aluminum shells available in 10 colors, aiming to help users blend medical devices with personal style.
The Series D expansion also serves as an endorsement of ViCentra’s operational trajectory, the company said, after a year in which it doubled its user base to more than 4,000 and generated associated revenue growth. ViCentra attributed its momentum to broader manufacturing capacity and rising adoption in Germany—described by the company as the world’s second-largest insulin pump market—along with continued growth in the Netherlands and France.
Chief Executive Officer Tom Arnold said the company’s 2026 focus is converting demand into satisfied users through continued emphasis on quality and performance, with an internal goal of nearly tripling the European user base by the end of 2026. ViCentra said the strengthened balance sheet will support both near-term manufacturing scale-up and the commercial infrastructure required to support a growing installed base in its core European markets.
ViCentra also noted that members of its leadership team, including Arnold, plan to be in the U.S. for meetings with investors and strategic partners during the J.P. Morgan Healthcare Conference week in San Francisco, and that the company expects to attend the LSI USA ’26 Emerging Medtech Summit in Dana Point in March.
KEY QUOTE:
“The past year has been transformative for ViCentra. This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands, and France, and ensures that we remain on course for our planned U.S. market access. Our goal for 2026 is clear: convert our current high demand into satisfied users through uncompromising quality and performance and nearly triple our European user base by the end of 2026.”
Tom Arnold, Chief Executive Officer, ViCentra
